A Single-center, Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics After Single-dose Administration of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects
Latest Information Update: 08 Nov 2019
At a glance
- Drugs Cenerimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Idorsia Pharmaceuticals
Most Recent Events
- 05 Nov 2019 Status changed from recruiting to completed.
- 12 Aug 2019 Status changed from not yet recruiting to recruiting.
- 12 Aug 2019 New trial record